Regeneron Pharmaceuticals, Inc.
NASDAQ:REGNBiotechnology
-$5.45 today
- Market cap
- $97.80B
- Beta
- 0.24
- P/E (TTM)
- 14.2
- EPS (TTM)
- $42.53
- Dividend yield
- 0.60%
Volume 0.70M
Average 0.91M
REGN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Regeneron Pharmaceuticals, Inc.NASDAQ: REGN
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $2.34B (cash outflow) rose 107.8% year over year, ahead of the +16.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 192.3% from the prior quarter. Over 3 fiscal years it compounded at +54.4% a year.
Context
- Financing cash flow amounted to 25.9% of revenue in FY2025, up 10.4 pp from a year earlier.
- Financing cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +107.8% holds above the trailing-twelve-month pace of +16.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (3.72B) USD
- Year-over-year change
- -68.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.72B) | -68.8% |
| FY2024 | 2024-12-31 | (2.2B) | -22.9% |
| FY2023 | 2023-12-31 | (1.79B) | -77.4% |
| FY2022 | 2022-12-31 | (1.01B) | -0.3% |
| FY2021 | 2021-12-31 | (1.01B) | — |
Financing Cash Flow vs competitors
How REGN compares with its peers on the latest reported figures
- REGN's LTM Jun 2026 financing cash flow of $4.65B is the 4th largest of the 9 companies compared; the peer median is $322.09M.
- Its year-over-year change of +16.5% is the 4th highest of 8, against a peer median of +13.0%.
- Financing cash flow amounts to 29.9% of revenue for REGN, versus a peer median of 13.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $5.39B | +9.1% | +3.4% | 8.7% | |
| LTM Jun 2026 | $4.96B | — | — | 120.1% | |
| LTM Jun 2026 | $4.65B | +13.0% | +6.2% | 15.3% | |
| LTM Jun 2026 | $4.65B | +16.5% | +54.4% | 29.9% | |
| LTM Jun 2026 | $4.13B | -65.2% | +39.1% | 10.8% | |
| LTM Jun 2026 | $1.04B | +3214.4% | -44.4% | 10.5% | |
| LTM Mar 2026 | $557.83M | +3601.6% | +628.3% | 1072.0% | |
| LTM Jun 2026 | $472.2M | +102.8% | -10.1% | 0.8% | |
| LTM Mar 2026 | $171.98M | +5.5% | — | 2258.5% | |
| Peer median (excluding REGN) | $322.09M | +13.0% | +4.8% | 13.0% | |
Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 8.08B | 4.34B | 3.95B | 4.41B | 4.5B |
| Depreciation & Amortization | 286.2M | 341.4M | 421M | 482.9M | 543.7M |
| Deferred Income Tax | (147.1M) | (746.4M) | (837.8M) | (757.3M) | (785.4M) |
| Stock-Based Compensation | 601.7M | 725M | 885M | 982.8M | 993.7M |
| Change in Working Capital | (1.92B) | (243.3M) | (94.1M) | (618.3M) | 532.6M |
| Accounts Receivables | (1.93B) | 707.8M | (338.8M) | (554M) | 498.1M |
| Inventory | (494.3M) | (696.5M) | (271.7M) | (619.7M) | (275.3M) |
| Accounts Payables | 866.1M | (138.4M) | 598.6M | 735.1M | 736.8M |
| Other Working Capital | (360.9M) | (116.2M) | (82.2M) | (179.7M) | (427M) |
| Other Non-Cash Items | 181.7M | 599.8M | 266.3M | (82.2M) | (810.6M) |
| Operating Cash Flow | 7.08B | 5.01B | 4.59B | 4.42B | 4.98B |
| Capital Expenditures | (551.9M) | (590.1M) | (926.4M) | (755.9M) | (898.4M) |
| Acquisitions (Net) | 551.9M | (230.3M) | (54.9M) | (16.5M) | (3.3M) |
| Purchases of Investments | (7.05B) | (7.49B) | (11.65B) | (16.62B) | (10.96B) |
| Sales of Investments | 2.22B | 5.55B | 9.44B | 15.03B | 11.55B |
| Other Investing Activities | (551.9M) | (1.03B) | 0 | (105.6M) | 0 |
| Investing Cash Flow | (5.38B) | (3.78B) | (3.19B) | (2.47B) | (629.1M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.67B | 1.52B | 1.15B | 1.47B | 635.9M |
| Common Stock Repurchased | (2.68B) | (2.53B) | (2.24B) | (3.63B) | (3.97B) |
| Dividends Paid | 0 | 0 | 0 | 0 | (370.3M) |
| Other Financing Activities | (1.03B) | (445.7M) | (700.6M) | (33.4M) | (10.3M) |
| Financing Cash Flow | (1.01B) | (1.01B) | (1.79B) | (2.2B) | (3.72B) |
| Effect of Forex Changes | 0 | 0 | (400K) | (700K) | 300K |
| Net Change in Cash | 690.8M | 221.3M | (381.6M) | (248.8M) | 634.7M |
| Free Cash Flow | 6.53B | 4.42B | 3.67B | 3.66B | 4.08B |
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
Intrinsic Alpha fair value
Locked
Current Price
$945.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.